Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Fluticasone furoate, umeclidinium bromide, and vilanterol as a combination therapy for chronic obstructive pulmonary disease.

Parri G, Nieri D, Roggi MA, Vagaggini B, Celi A, Paggiaro P.

Expert Rev Respir Med. 2018 Dec;12(12):997-1005. doi: 10.1080/17476348.2018.1548936. Epub 2018 Nov 28.

PMID:
30463451
2.

Physical activity patterns and clusters in 1001 patients with COPD.

Mesquita R, Spina G, Pitta F, Donaire-Gonzalez D, Deering BM, Patel MS, Mitchell KE, Alison J, van Gestel AJ, Zogg S, Gagnon P, Abascal-Bolado B, Vagaggini B, Garcia-Aymerich J, Jenkins SC, Romme EA, Kon SS, Albert PS, Waschki B, Shrikrishna D, Singh SJ, Hopkinson NS, Miedinger D, Benzo RP, Maltais F, Paggiaro P, McKeough ZJ, Polkey MI, Hill K, Man WD, Clarenbach CF, Hernandes NA, Savi D, Wootton S, Furlanetto KC, Cindy Ng LW, Vaes AW, Jenkins C, Eastwood PR, Jarreta D, Kirsten A, Brooks D, Hillman DR, Sant'Anna T, Meijer K, Dürr S, Rutten EP, Kohler M, Probst VS, Tal-Singer R, Gil EG, den Brinker AC, Leuppi JD, Calverley PM, Smeenk FW, Costello RW, Gramm M, Goldstein R, Groenen MT, Magnussen H, Wouters EF, ZuWallack RL, Amft O, Watz H, Spruit MA.

Chron Respir Dis. 2017 Aug;14(3):256-269. doi: 10.1177/1479972316687207. Epub 2017 Feb 24.

3.

Analysis of nocturnal actigraphic sleep measures in patients with COPD and their association with daytime physical activity.

Spina G, Spruit MA, Alison J, Benzo RP, Calverley PMA, Clarenbach CF, Costello RW, Donaire-Gonzalez D, Dürr S, Garcia-Aymerich J, van Gestel AJR, Gramm M, Hernandes NA, Hill K, Hopkinson NS, Jarreta D, Kohler M, Kirsten AM, Leuppi JD, Magnussen H, Maltais F, Man WD, McKeough ZJ, Mesquita R, Miedinger D, Pitta F, Singh SJ, Smeenk FWJM, Tal-Singer R, Vagaggini B, Waschki B, Watz H, Wouters EFM, Zogg S, den Brinker AC.

Thorax. 2017 Aug;72(8):694-701. doi: 10.1136/thoraxjnl-2016-208900. Epub 2017 Jan 12.

4.

Cell-derived microparticles and the lung.

Nieri D, Neri T, Petrini S, Vagaggini B, Paggiaro P, Celi A.

Eur Respir Rev. 2016 Sep;25(141):266-77. doi: 10.1183/16000617.0009-2016. Review.

5.

An observation of prescription behaviors and adherence to guidelines in patients with COPD: real world data from October 2012 to September 2014.

Visentin E, Nieri D, Vagaggini B, Peruzzi E, Paggiaro P.

Curr Med Res Opin. 2016 Sep;32(9):1493-502. doi: 10.1080/03007995.2016.1182900. Epub 2016 May 24.

PMID:
27215310
6.

Sputum inflammatory cells in COPD patients classified according to GOLD 2011 guidelines.

Bartoli ML, Costa F, Malagrinò L, Nieri D, Antonelli S, Decusatis G, Simone CD, Santerini S, Cianchetti S, Latorre M, Vagaggini B, Paggiaro P.

Eur Respir J. 2016 Mar;47(3):978-80. doi: 10.1183/13993003.00784-2015. Epub 2016 Feb 4. No abstract available.

7.

Neutrophilic Bronchial Inflammation Correlates with Clinical and Functional Findings in Patients with Noncystic Fibrosis Bronchiectasis.

Dente FL, Bilotta M, Bartoli ML, Bacci E, Cianchetti S, Latorre M, Malagrinò L, Nieri D, Roggi MA, Vagaggini B, Paggiaro P.

Mediators Inflamm. 2015;2015:642503. doi: 10.1155/2015/642503. Epub 2015 Dec 27.

8.

Assessing exercise performance during exacerbations of chronic obstructive pulmonary disease: work smarter, not harder!

Osadnik C, Vagaggini B, Paggiaro P.

Respiration. 2015;90(3):189-90. doi: 10.1159/000439314. Epub 2015 Sep 4. No abstract available.

9.

Can Sputum Eosinophilia Be a Constant Feature in Severe Refractory Asthmatics? A 3-Year Longitudinal Study.

Dente FL, Latorre M, Novelli F, Cianchetti S, Bartoli ML, Bacci E, Di Franco A, Vagaggini B, Celi A, Paggiaro P.

Int Arch Allergy Immunol. 2015;166(4):287-90. doi: 10.1159/000381853. Epub 2015 May 9.

10.

Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study.

Talini D, Novelli F, Bacci E, Bartoli M, Cianchetti S, Costa F, Dente FL, Di Franco A, Latorre M, Malagrinò L, Vagaggini B, Celi A, Paggiaro P.

BMJ Open. 2015 Jan 5;5(1):e005748. doi: 10.1136/bmjopen-2014-005748.

11.

Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.

Latorre M, Novelli F, Vagaggini B, Braido F, Papi A, Sanduzzi A, Santus P, Scichilone N, Paggiaro P.

Pulm Pharmacol Ther. 2015 Feb;30:44-50. doi: 10.1016/j.pupt.2014.10.006. Epub 2014 Nov 6. Review.

PMID:
25445928
12.

Tiotropium: a new therapeutic option in asthma.

Novelli F, Costa F, Latorre M, Malagrinò L, Celi A, Vagaggini B, Paggiaro P.

Monaldi Arch Chest Dis. 2013 Sep-Dec;79(3-4):109-15. Review.

13.

Markers of small airway involvement and asthma control in patients with moderate-to-severe asthma.

Malagrinò L, Catapano G, Novelli F, Bacci E, Costa F, Dente FL, Di Franco A, Latorre M, Vagaggini B, Celi A, Paggiaro P.

Ann Allergy Asthma Immunol. 2014 Jun;112(6):551-2. doi: 10.1016/j.anai.2014.03.009. Epub 2014 Apr 18. No abstract available.

PMID:
24746898
14.

Are sputum eosinophil cationic protein and eosinophils differently associated with clinical and functional findings of asthma?

Cianchetti S, Bacci E, Ruocco L, Pavia T, Bartoli ML, Cardini C, Costa F, Di Franco A, Malagrinò L, Novelli F, Vagaggini B, Celi A, Dente F, Paggiaro P.

Clin Exp Allergy. 2014;44(5):673-80. doi: 10.1111/cea.12236.

PMID:
24245689
15.

Baseline airway inflammation may be a determinant of the response to ozone exposure in asthmatic patients.

Bartoli ML, Vagaggini B, Malagrinò L, Bacci E, Cianchetti S, Dente FL, Novelli F, Costa F, Paggiaro P.

Inhal Toxicol. 2013 Feb;25(3):127-33. doi: 10.3109/08958378.2013.763313.

PMID:
23421484
16.

Mild improvement in symptoms and pulmonary function in a long-term follow-up of patients with toluene diisocyanate-induced asthma.

Talini D, Novelli F, Bacci E, Costa F, Dente FL, Di Franco A, Malagrinò L, Vagaggini B, Paggiaro P.

Int Arch Allergy Immunol. 2013;161(2):189-94. doi: 10.1159/000338993. Epub 2013 Jan 23.

PMID:
23343863
17.

Transient sputum eosinophilia may occur over time in non-eosinophilic asthma and this is not prevented by salmeterol.

Bacci E, Latorre M, Cianchetti S, Bartoli M, Costa F, Di Franco A, Malagrinò L, Novelli F, Vagaggini B, Dente FL, Paggiaro P.

Respirology. 2012 Nov;17(8):1199-206. doi: 10.1111/j.1440-1843.2012.02242.x.

PMID:
22882543
18.

Cytokines in induced sputum: a role for the ratio of IL-6/IL-13 in the differentiation of asthma and chronic obstructive pulmonary disease?

Dente FL, Bacci E, Vagaggini B, Paggiaro P.

Respiration. 2012;84(2):98-100. Epub 2012 Apr 5. No abstract available.

19.

Poor response to inhaled corticosteroids in obese, asthmatic patients.

Paggiaro P, Bacci E, Dente F, Vagaggini B.

Ann Allergy Asthma Immunol. 2012 Apr;108(4):217-8. doi: 10.1016/j.anai.2012.02.011. No abstract available.

PMID:
22469438
20.

Asthma control test (ACT): comparison with clinical, functional, and biological markers of asthma control.

Melosini L, Dente FL, Bacci E, Bartoli ML, Cianchetti S, Costa F, Di Franco A, Malagrinò L, Novelli F, Vagaggini B, Paggiaro P.

J Asthma. 2012 Apr;49(3):317-23. doi: 10.3109/02770903.2012.661008. Epub 2012 Mar 9.

PMID:
22401649
21.

May the reduction of exposure to specific sensitizers be an alternative to work cessation in occupational asthma? Results from a follow-up study.

Talini D, Novelli F, Melosini L, Bacci E, Bartoli ML, Cianchetti S, Dente FL, Di Franco A, Vagaggini B, Paggiaro PL.

Int Arch Allergy Immunol. 2012;157(2):186-93. doi: 10.1159/000327550. Epub 2011 Oct 7.

PMID:
21986104
22.

Malondialdehyde in exhaled breath condensate as a marker of oxidative stress in different pulmonary diseases.

Bartoli ML, Novelli F, Costa F, Malagrinò L, Melosini L, Bacci E, Cianchetti S, Dente FL, Di Franco A, Vagaggini B, Paggiaro PL.

Mediators Inflamm. 2011;2011:891752. doi: 10.1155/2011/891752. Epub 2011 Jun 16.

23.

Comparison between Airway Responses to High versus Low Molecular Weight Compounds in Occupational Asthma.

Talini D, Novelli F, Bacci E, Dente FL, De Santis M, Di Franco A, Melosini L, Vagaggini B, Paggiaro PL.

J Allergy (Cairo). 2011;2011:781470. doi: 10.1155/2011/781470. Epub 2011 May 25.

24.

Acute administration of bronchodilators on exercise tolerance in treated COPD patients.

Vagaggini B, Nieri D, Malagrinò L, Antonelli S, De Cusatis G, De Simone C, Costa F, Paggiaro PL.

Pulm Pharmacol Ther. 2011 Feb;24(1):49-54. doi: 10.1016/j.pupt.2010.10.008. Epub 2010 Oct 21.

PMID:
20970517
25.

Effects of oral prednisone on sputum eosinophils and cytokines in patients with severe refractory asthma.

Dente FL, Bacci E, Bartoli ML, Cianchetti S, Costa F, Di Franco A, Malagrinò L, Vagaggini B, Paggiaro P.

Ann Allergy Asthma Immunol. 2010 Jun;104(6):464-70. doi: 10.1016/j.anai.2010.04.003.

PMID:
20568377
26.

Beclomethasone dipropionate blunts allergen-induced early increase in urinary LTE4.

Bartoli ML, Dente FL, Bancalari L, Bacci E, Cianchetti S, Di Franco A, Vagaggini B, Paggiaro PL.

Eur J Clin Invest. 2010 Jun;40(6):566-9. doi: 10.1111/j.1365-2362.2010.02297.x. Epub 2010 Apr 28.

PMID:
20456484
27.

Efficacy of standard rehabilitation in COPD outpatients with comorbidities.

Crisafulli E, Gorgone P, Vagaggini B, Pagani M, Rossi G, Costa F, Guarriello V, Paggiaro P, Chetta A, de Blasio F, Olivieri D, Fabbri LM, Clini EM.

Eur Respir J. 2010 Nov;36(5):1042-8. doi: 10.1183/09031936.00203809. Epub 2010 Apr 22.

28.

Increase in markers of airway inflammation after ozone exposure can be observed also in stable treated asthmatics with minimal functional response to ozone.

Vagaggini B, Bartoli ML, Cianchetti S, Costa F, Bacci E, Dente FL, Di Franco A, Malagrinò L, Paggiaro P.

Respir Res. 2010 Jan 19;11:5. doi: 10.1186/1465-9921-11-5.

29.

Clinical predictors of the efficacy of a pulmonary rehabilitation programme in patients with COPD.

Vagaggini B, Costa F, Antonelli S, De Simone C, De Cusatis G, Martino F, Santerini S, Paggiaro P.

Respir Med. 2009 Aug;103(8):1224-30. doi: 10.1016/j.rmed.2009.01.023. Epub 2009 Mar 21.

30.

Biological markers in induced sputum of patients with different phenotypes of chronic airway obstruction.

Bartoli ML, Di Franco A, Vagaggini B, Bacci E, Cianchetti S, Dente FL, Tonelli M, Paggiaro PL.

Respiration. 2009;77(3):265-72. doi: 10.1159/000176385. Epub 2008 Dec 11.

31.

Magnitude of late asthmatic response to allergen in relation to baseline and allergen-induced sputum eosinophilia in mild asthmatic patients.

Dente FL, Bacci E, Bartoli ML, Cianchetti S, Di Franco A, Costa F, Vagaggini B, Paggiaro PL.

Ann Allergy Asthma Immunol. 2008 May;100(5):457-62. doi: 10.1016/S1081-1206(10)60471-1.

PMID:
18517078
32.

Can hypertonic saline inhalation influence preformed chemokine and mediator release in induced sputum of chronic obstructive pulmonary disease patients? Comparison with isotonic saline.

Cianchetti S, Bacci E, Bartoli ML, Ruocco L, Pavia T, Dente FL, Di Franco A, Vagaggini B, Paggiaro P.

Clin Exp Allergy. 2007 Dec;37(12):1819-26. Epub 2007 Oct 17.

PMID:
17941910
33.

Some factors influencing quality of spontaneous or induced sputum for inflammatory cell analysis.

Bartoli ML, Bacci E, Cianchetti S, Dente FL, Di Franco A, Vagaggini B, De Santis M, Masino E, Paggiaro PL.

Monaldi Arch Chest Dis. 2007 Jun;67(2):81-3.

PMID:
17695690
34.

Profiles of proinflammatory cytokines in sputum from different groups of severe asthmatic patients.

Dente FL, Carnevali S, Bartoli ML, Cianchetti S, Bacci E, Di Franco A, Vagaggini B, Paggiaro P.

Ann Allergy Asthma Immunol. 2006 Sep;97(3):312-20.

PMID:
17042136
35.

Prednisone blunts airway neutrophilic inflammatory response due to ozone exposure in asthmatic subjects.

Vagaggini B, Cianchetti S, Bartoli M, Ricci M, Bacci E, Dente FL, Di Franco A, Paggiaro P.

Respiration. 2007;74(1):61-8. Epub 2006 Oct 4.

PMID:
17028419
36.

Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients.

Bacci E, Cianchetti S, Bartoli M, Dente FL, Di Franco A, Vagaggini B, Paggiaro P.

Chest. 2006 Mar;129(3):565-72.

PMID:
16537853
37.

Minimal tolerance to the bronchoprotective effect of inhaled salmeterol/fluticasone combination on allergene challenge.

Paggiaro PL, Giannini D, Di Franco A, Bacci E, Dente FL, Vagaggini B, Tonelli M, Zingoni M.

Pulm Pharmacol Ther. 2006;19(6):425-9. Epub 2005 Dec 2.

PMID:
16326121
38.

Efficacy of nebulized flunisolide combined with salbutamol and ipratropium bromide in stable patients with moderate-to-severe chronic obstructive pulmonary disease.

Paggiaro PL, Vagaggini B, Di Franco A, Zingoni M, Fano M, Biraghi M.

Respiration. 2006;73(5):603-9. Epub 2005 Nov 15.

PMID:
16293958
39.

Inhaled fluticasone propionate is effective as well as oral prednisone in reducing sputum eosinophilia during exacerbations of asthma which do not require hospitalization.

Di Franco A, Bacci E, Bartoli ML, Cianchetti S, Dente FL, Taccola M, Vagaggini B, Zingoni M, Paggiaro PL.

Pulm Pharmacol Ther. 2006;19(5):353-60. Epub 2005 Nov 11.

PMID:
16289980
40.

Predictors of symptom recurrence after low-dose inhaled corticosteroid cessation in mild persistent asthma.

Tonelli M, Bacci E, Dente FL, Bartoli ML, Cianchetti S, Di Franco A, Vagaggini B, Zingoni M, Paggiaro PL.

Respir Med. 2006 Apr;100(4):622-9. Epub 2005 Oct 25.

41.

Granulocyte markers in hypertonic and isotonic saline-induced sputum of asthmatic subjects.

Cianchetti S, Bacci E, Ruocco L, Bartoli ML, Ricci M, Pavia T, Dente FL, Di Franco A, Vagaggini B, Paggiaro PL.

Eur Respir J. 2004 Dec;24(6):1018-24.

42.

One week treatment with salmeterol does not prevent early and late asthmatic responses and sputum eosinophilia induced by allergen challenge in asthmatics.

Dente FL, Bacci E, Bartoli ML, Cianchetti S, Di Franco A, Giannini D, Taccola M, Vagaggini B, Paggiaro PL.

Pulm Pharmacol Ther. 2004;17(3):147-53.

PMID:
15123224
43.

[Clinical aspects of chronic obstructive pulmonary disease].

Paggiaro P, Vagaggini B.

Ann Ist Super Sanita. 2003;39(4):519-28. Review. Italian.

44.

Clinical assessment of asthma severity partially corresponds to sputum eosinophilic airway inflammation.

Bartoli ML, Bacci E, Carnevali S, Cianchetti S, Dente FL, Di Franco A, Giannini D, Taccola M, Vagaggini B, Paggiaro PL.

Respir Med. 2004 Feb;98(2):184-93.

45.

Shuttle walking test and 6-minute walking test induce a similar cardiorespiratory performance in patients recovering from an acute exacerbation of chronic obstructive pulmonary disease.

Vagaggini B, Taccola M, Severino S, Marcello M, Antonelli S, Brogi S, De Simone C, Giardina A, Paggiaro PL.

Respiration. 2003 Nov-Dec;70(6):579-84.

PMID:
14732787
46.

Tolerance to the protective effect of salmeterol in mild untreated asthmatics.

Giannini D, Di Franco A, Bacci E, Dente FL, Vagaggini B, Taccola M, Tonelli M, Zingoni M, Paggiaro P.

Pulm Pharmacol Ther. 2003;16(6):355-60.

PMID:
14580927
47.

Short-term effect of the addition of leukotriene receptor antagonists to the current therapy in severe asthmatics.

Tonelli M, Zingoni M, Bacci E, Dente FL, Di Franco A, Giannini D, Taccola M, Vagaggini B, Paggiaro PL.

Pulm Pharmacol Ther. 2003;16(4):237-40.

PMID:
12850127
48.

Analysis of sputum cell counts during spontaneous moderate exacerbations of asthma in comparison to the stable phase.

Di Franco A, Bartoli ML, Carnevali S, Cianchetti S, Bacci E, Dente FL, Giannini D, Taccola M, Vagaggini B, Paggiaro PL.

J Asthma. 2003 Apr;40(2):155-62.

PMID:
12765317
49.

Fifty microg b.i.d. of inhaled fluticasone propionate (FP) are effective in stable asthmatics previously treated with a higher dose of FP.

Giannini D, Di Franco A, Tonelli M, Bartoli ML, Carnevali S, Cianchetti S, Bacci E, Dente FL, Vagaggini B, Paggiaro PL.

Respir Med. 2003 May;97(5):463-7.

50.

Induced sputum is a reproducible method to assess airway inflammation in asthma.

Bacci E, Cianchetti S, Carnevali S, Bartoli ML, Dente FL, Di Franco A, Giannini D, Vagaggini B, Paggiaro PL.

Mediators Inflamm. 2002 Oct;11(5):293-8.

Supplemental Content

Loading ...
Support Center